A new study published in the New England Journal of Medicine reveals that medications widely used for diabetes and obesity may offer significant benefits for patients with liver disease, adding to the growing list of potential applications for these popular drugs.

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

There could be a new use for semaglutide, the main ingredient of weight loss and diabetes drugs Wegovy and Ozempic. Dr. Jon LaPook explains a study sponsored by the drugmaker found it could treat a common liver disease by reducing inflammation and scarring.